Research Topics
Genomes and Genes
| aminopyridinesSummarySummary: Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond. Top Publications
Research Grants
| Scientific Experts
|
Detail Information
Publications
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseaseArmin Hatzelmann
Nycomed GmbH, Konstanz, Germany
Pulm Pharmacol Ther 23:235-56. 2010..This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favourably affect the extrapulmonary effects of the disease...
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsPeter M A Calverley
School of Clinical Sciences, Liverpool, UK
Lancet 374:685-94. 2009..We therefore investigated whether roflumilast would reduce the frequency of exacerbations requiring corticosteroids in patients with COPD...
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseasePeter M A Calverley
Department of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool L97AL, UK
Am J Respir Crit Care Med 176:154-61. 2007..Whether treatment is effective in more severe COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages III and IV) over a longer period is unknown...
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLeonardo M Fabbri
University of Modena and Reggio Emilia, Modena, Italy
Lancet 374:695-703. 2009..The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated...
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPDStephen I Rennard
Nebraska Medical Center, Omaha, Nebraska, USA
Respir Res 12:18. 2011..This led to the question of whether a responsive subset existed that could be investigated further...
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDDiana C Grootendorst
Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
Thorax 62:1081-7. 2007..Results from in vitro studies with roflumilast indicate that it has anti-inflammatory properties that may be applicable for the treatment of COPD...
S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitroC Mouta Carreira
Center for Molecular Medicine, Maine Medical Center Research Institute, South Portland, Maine 04106, USA
J Biol Chem 273:22224-31. 1998....
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung diseaseFrancisco J Soto
Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
Curr Opin Pulm Med 11:129-34. 2005..Novel anti-inflammatory therapies such as selective phosphodiesterase 4 (PDE4) inhibitors are in clinical development. Their potential role in the management of COPD is described in this review...
Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed micePiero A Martorana
Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy
BMC Pulm Med 8:17. 2008..Here we investigated the effects of roflumilast on the volume density (VV) of the inflammatory cells present in the lungs after chronic cigarette smoke exposure...
PDE4 inhibitors: a review of current developments (2005 - 2009)Lluís Pagès
Almirall R and D Centre, Department of Medicinal Chemistry, Laurea Miro 408 410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
Expert Opin Ther Pat 19:1501-19. 2009..Despite the sound preclinical database and some promising data from clinical trials, development of PDE4 inhibitors for the treatment of inflammatory or neurological diseases has been hampered by dose-limiting class-related side effects...
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjectsNassr Nassr
Nycomed GmbH, 78467 Konstanz, Germany
Br J Clin Pharmacol 68:580-7. 2009..Roflumilast is metabolized by CYP3A4 and CYP1A2, with further involvement of CYP2C19 and extrahepatic CYP1A1. In vivo, roflumilast N-oxide contributes >90% to the total PDE4 inhibitory activity...
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivoKerryn McCluskie
Department of Pharmacology, Theravance Inc, South San Francisco, California, USA
J Pharmacol Exp Ther 319:468-76. 2006..The proinflammatory cytokines KC and IL-8 therefore may provide surrogate biomarkers, both in preclinical animal models and in the clinic, to assess potential proinflammatory effects of this class of compounds...
Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxideOliver von Richter
Exploratory Medicine, ALTANA Pharma AG, Konstanz, Germany
Clin Pharmacokinet 46:613-22. 2007....
Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of respondingPaul J Fletcher
Departments of Psychiatry and Psychology, University of Toronto, Toronto, Ontario, Canada
Neuropsychopharmacology 27:576-86. 2002..These results indicate distinct, and in some cases opposite, effects of a 5-HT(2A) compared with a 5-HT(2C) receptor antagonist on various cocaine-mediated behavioral effects...
Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaineSylvia Navailles
Unité Mixte de Recherche Centre National de la Recherche Scientifique UMR CNRS 5541, Universite Victor Segalen Bordeaux 2, Bordeaux Cedex, France
Neuropsychopharmacology 33:237-46. 2008....
5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscTadayoshi Mikami
Drug Safety Research and Development, Tokyo Laboratories, Pfizer Global Research and Development, Pfizer Inc, 3 22 7 Yoyogi, Shibuya, Tokyo 151 8589, Japan
J Pharmacol Exp Ther 325:190-9. 2008..Therefore, CJ-033,466 could be used to treat gastroparesis, providing better gastroprokinetics and reduced side effects mediated by the other receptors...
Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event modelGezim Lahu
Department of Pharmacometrics and Pharmacokinetics, Nycomed GmbH, Byk Gulden Strasse 2, Konstanz, Germany
Clin Pharmacokinet 49:589-606. 2010..Both roflumilast and its metabolite roflumilast N-oxide have anti-inflammatory properties that contribute to overall pharmacological activity...
A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitroF Sabatini
Pulmonary Disease Unit, G Gaslini Institute, Largo G Gaslini 5, 16147 Genoa, Italy
Pulm Pharmacol Ther 23:283-91. 2010..Taken together, these findings indicate that roflumilast N-oxide directly targets human lung fibroblasts, which may at least partially explain the efficacy of roflumilast to mitigate a pulmonary fibrotic response in vivo...
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitorsJ Nicole Hamblin
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
Bioorg Med Chem Lett 18:4237-41. 2008....
No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidineGabriele M Böhmer
Department of Clinical Pharmacology, University Hospital of Tubingen, Tubingen, Germany
J Clin Pharmacol 51:594-602. 2011..These moderate changes indicate that dose adjustment of roflumilast is not required when coadministered with a weak inhibitor of CYP1A2, CYP3A, and CYP2C19, such as cimetidine...
Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxideGezim Lahu
Nycomed GmbH, Konstanz, Germany
J Clin Pharmacol 51:586-93. 2011..Roflumilast was well tolerated both alone and in combination with enoxacin. A weak interaction was shown between roflumilast and enoxacin, as mean tPDE4i increased by 25%, but is unlikely to have clinical relevance...
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary diseaseBrian J Lipworth
Department of Medicine and Therapeutics, Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
Lancet 365:167-75. 2005..Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor...
Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeabilityM J Sanz
Department of Pharmacology, University of Valencia, Valencia, Spain
Br J Pharmacol 152:481-92. 2007..The present study addressed the effects of the investigational PDE4 inhibitor roflumilast on leukocyte-endothelial cell interactions and endothelial permeability in vivo and in vitro...
An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trialJie Liu
Department of Oral Medicine, West China College of Stomatology, Suchuan University, Sichuan, China
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:475-81. 2006..05). No systemic side effects were reported. CONCLUSIONS: Amlexanox oral adhesive tablets are effective and safe in reducing aphthous ulcer pain and lesion size, as well as erythema and exudation in this Chinese cohort...
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivoWolfgang Timmer
Byk Gulden Pharmaceuticals, Konstanz, Germany
J Clin Pharmacol 42:297-303. 2002..It is concluded that roflumilast is effective in the treatment of exercise-induced asthma. This result was accompanied by a significant reduction of TNF-alpha levels ex vivo. Treatment with roflumilast was safe and well tolerated...
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjectsNassr Nassr
ALTANA Pharma AG, 78467 Konstanz, Germany
Br J Clin Pharmacol 63:365-70. 2007..The aim of this study was to investigate the effects of roflumilast, an investigational PDE4 inhibitor for the treatment of COPD and asthma, on the pharmacokinetics of the CYP3A probe drug midazolam and its major metabolites...
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactionsEmmerentia van Schalkwyk
Department of Internal Medicine, University of Stellenbosch, Cape Town
J Allergy Clin Immunol 116:292-8. 2005..Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma...
Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjectsBernhard Hauns
Department of Clinical Pharmacology, ALTANA Pharma AG, Byk Gulden Str 2, D 78467 Konstanz, Germany
J Clin Pharmacol 46:1146-53. 2006..91; 90% CI, 0.79-1.04; PE, 0.99; 90% CI, 0.92-1.06) occurred. Because roflumilast N-oxide is the major contributor to roflumilast's overall pharmacologic effects, these findings suggest that roflumilast can be taken with or without food...
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expressionMaria Jesus Sanz
Department of Pharmacology, Faculty of Medicine, University of Valencia, Avenida Blasco Ibanez 15, E 46010 Valencia, Spain
Pharmacol Ther 106:269-97. 2005..These new drugs may also offer opportunities for treatment of other inflammatory diseases...
The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulcerationB Murray
The Oral Science Research Centre, School of Dentistry, Queen's University Belfast, Royal Group Hospitals and Dental Hospital, Belfast, UK
J Oral Pathol Med 35:117-22. 2006..CONCLUSION: The OraDisc prevents ulcers from developing when compared with the vehicle patch...
Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigsLutz Wollin
ALTANA Pharma, Konstanz, Germany
J Asthma 42:873-8. 2005..06 mg/kg) and LTB4 (ID50 = 0.05 mg/kg) release versus placebo-treated animals. Roflumilast did not affect LTD4-induced bronchoconstriction. These findings support the role of roflumilast as an anti-inflammatory treatment for asthma...
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitorsL Wollin
ALTANA Pharma, Byk Gulden Strasse 2, 78467 Konstanz, Germany
Pulm Pharmacol Ther 19:343-52. 2006..This study suggests that roflumilast has anti-inflammatory action and provides rationale for the investigation of roflumilast in asthmatic patients...
A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulcerationBrenda Murray
The Oral Science Research Centre, School of Dentistry, Queen's University Belfast, UK
J Oral Pathol Med 34:413-9. 2005..01) compared to no treatment. CONCLUSION: Treatment with Aphtheal at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop...
Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activationHyun Jeong Kwak
Laboratory of Molecular Pharmacology and Physiology, Medicinal Science Division, Korea Research Institute of Chemical Technology, P.O. Box 107, Yusung-gu, Taejon 305-343, Korea
J Pharmacol Exp Ther 315:1188-95. 2005..These results suggest that the inhibitory activity of roflumilast on the production of inflammatory mediators seems to be mediated via inhibition of NF-kappaB, p38 MAP kinase, and JNK activation in macrophages...
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialKlaus F Rabe
Leiden University Medical Centre, Leiden, Netherlands
Lancet 366:563-71. 2005..There are few treatment options for the disease. This study assessed the efficacy and safety of roflumilast, a phosphodiesterase-4 inhibitor, in patients with moderate to severe COPD...
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjectsT D Bethke
ALTANA Pharma AG, Konstanz, Germany
Int J Clin Pharmacol Ther 44:572-9. 2006..10 (0.99, 1.21), 1.08 (0.91, 1.28). The combination of both drugs was well tolerated. CONCLUSION: There were no relevant pharmacokinetic interactions between roflumilast and salbutamol at therapeutically effective doses...
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitorThomas D Bethke
Department of Clinical Development Strategy, ALTANA Pharma AG, Konstanz, Germany
J Clin Pharmacol 47:26-36. 2007..Repeated oral dosing with roflumilast 250 and 500 microg once daily was well tolerated...
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactionsGabriele M Böhmer
Department of Clinical Pharmacology, University Hospital of Tubingen, Otfried Müller Str 45, D 72076 Tubingen, Germany
J Clin Pharmacol 49:389-97. 2009..Concomitant administration of both drugs was well tolerated. These findings suggest that no dose adjustment is warranted for either drug when roflumilast and montelukast are coadministered...
PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblastsShinsaku Togo
Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5885, USA
Am J Physiol Lung Cell Mol Physiol 296:L959-69. 2009..The present study supports the concept that PDE4 inhibitors may attenuate fibroblast activities that can lead to fibrosis and that PDE4 inhibitors may be particularly effective in the presence of TGF-beta1-induced fibroblast stimulation...
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxideGezim Lahu
Nycomed GmbH, Department of Pharmacometrics and Pharmacokinetics, Byk Gulden Str 2, 78467 Konstanz, Germany
J Clin Pharmacol 48:1339-49. 2008..No clinically relevant adverse events were observed. Coadministration of ketoconazole and roflumilast does not require dose adjustment of roflumilast...
Single-dose pharmacokinetics of roflumilast in children and adolescentsKathleen A Neville
Department of Pediatrics, University of Missouri Kansas City and the Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64079, USA
J Clin Pharmacol 48:978-85. 2008..1 and 0.8 microg/L per 1 microg/kg dose for adolescents and children, respectively), pharmacokinetic parameters for roflumilast and roflumilast N-oxide were not different between age groups and were similar to adults...
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trialJens M Hohlfeld
Department of Clinical Airway Research, Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Nikolai Fuchs Street 1A, D 30625 Hannover, Germany
Pulm Pharmacol Ther 21:616-23. 2008..Roflumilast, an investigational, targeted phosphodiesterase 4 inhibitor, reduces the in vitro and in vivo inflammatory activity of cells such as neutrophils, eosinophils, macrophages, and monocytes...
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilastVictoria Boswell Smith
The Sackler Institute of Pulmonary Pharmacology, King s College London School of Biomedical and Health Sciences, King s College London, Guys Campus, UK
Int J Chron Obstruct Pulmon Dis 2:121-9. 2007..This review will discuss the current standing of PDE4 inhibitors like roflumilast as novel treatments for COPD and the potential for developing nonemetic anti-inflammatory drugs...
The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonideRobert Hermann
ALTANA Pharma AG, Konstanz, Germany
J Clin Pharmacol 47:1005-13. 2007..67, 1.50). Coadministration of roflumilast and budesonide did not alter the steady-state disposition of each other and did not affect safety and tolerability of either drug...
Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusionAtsushi Kuno
Department of Physiology, MSB 3074, University of South Alabama, College of Medicine, Mobile, AL 36688, USA
J Mol Cell Cardiol 43:262-71. 2007..We propose that the key protective event in IPC occurs when PKC increases the heart's sensitivity to adenosine so that endogenous adenosine can activate A(2b)-dependent signaling...
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway ratsRichard W Chapman
Schering Plough Research Institute, Pulmonary and Peripheral Neurobiology M S 1700, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States
Eur J Pharmacol 571:215-21. 2007..These results support the development of inhaled PDE4 inhibitors for the treatment of asthma and COPD, particularly for the improvement of lung function...
Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitisM Rodriguez
Facultad de Odontologia, Universidad Nacional de Colombia, Bogota, Colombia
Oral Dis 13:490-4. 2007..To compare the effectiveness of two topical medications to reduce the pain and size of recurrent minor aphthous ulcers...
Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosisRobert Hermann
Exploratory Medicine, ALTANA Pharma AG, Konstanz, Germany
Clin Pharmacokinet 46:403-16. 2007..Roflumilast is being developed for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease and asthma...
Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilastNassr Nassr
Department of Exploratory Medicine, ALTANA Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz, Germany
J Clin Pharmacol 47:660-6. 2007
Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptorsTobias Eckle
Department of Anesthesiology and Intensive Care Medicine, Tubingen University Hospital, Hoppe Seyler Str 3, D 72076 Tubingen, Germany
Circulation 115:1581-90. 2007..Once generated, adenosine can activate cell-surface adenosine receptors (A1 AR, A2A AR, A2B AR, A3 AR). In the present study, we define the contribution of adenosine to cardioprotection by ischemic preconditioning...
Anxiolytic-like activity of SB-205384 in the elevated plus-maze test in miceJose Francisco Navarro
Facultad de Psicologia, Universidad de Malaga, Spain
Psicothema 18:100-4. 2006..These findings indicate that SB-205384 exhibits an anxiolytic-like profile in the elevated plus-maze test, suggesting that GABA-A receptors which contain the alpha3 subunit might be involved in regulation of anxiety...
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxideG Lahu
Nycomed GmbH formerly ALTANA Pharma AG, Konstanz, Germany
Int J Clin Pharmacol Ther 47:236-45. 2009..Both roflumilast and roflumilast N-oxide have similar intrinsic PDE4 inhibitory activity; the total PDE4 inhibition (tPDE4i) in humans is likely due to the combined effect of roflumilast and roflumilast N-oxide...
Metal-free catalysts for the hydrolysis of RNA derived from guanidines, 2-aminopyridines, and 2-aminobenzimidazolesUte Scheffer
Institute for Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Marie-Curie-Str. 11, 60439 Frankfurt am Main, Germany
J Am Chem Soc 127:2211-7. 2005..Conjugates of 10b with antisense oligonucleotides or RNA binding peptides, therefore, will be promising candidates as site specific artificial ribonucleases...
Treatment strategies for recurrent oral aphthous ulcersR W Barrons
Clinical Pharmacy, Xavier University of Louisiana, 1 Drexel Street, New Orleans, LA 70125 1098, USA
Am J Health Syst Pharm 58:41-50; quiz 51-3. 2001..Thalidomide is effective but, because of its toxicity and cost, should be used only as an alternative to oral corticosteroids. RAU can be effectively managed with a variety of topical and systemic medications...
In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatumSylvia Navailles
UMR CNRS, , Bordeaux Cedex, France
Neuropsychopharmacology 29:319-26. 2004..Furthermore, they show that 5-HT(2C) agonists, at variance with 5-HT(2C) antagonists, exert a preferential control on the impulse-stimulated release of DA...
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthmaRakesh K Kumar
Department of Pathology, University of New South Wales, Sydney, Australia
J Pharmacol Exp Ther 307:349-55. 2003..Roflumilast did not diminish accumulation of transforming growth factor-beta1, suggesting that it might affect remodeling by mechanisms distinct from glucocorticoids...
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitroN A Jones
Sackler Institute of Pulmonary Pharmacology, 5th Floor Hodgkin Building, Guy's Campus, St Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK
Pulm Pharmacol Ther 18:93-101. 2005..These data provide further evidence that selective PDE4 isoenzyme inhibitors can inhibit neutrophil degranulation, effects not shared by PDE3 inhibitors or theophylline...
Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein familyT Shishibori
Department of Chemistry, Kagawa Medical University, 1750 1, Miki cho, Kita gun, 761 0793 Kagawa, Japan
Biochem J 338:583-9. 1999..On the basis of these findings, we speculate that the three anti-allergic drugs might inhibit degranulation by binding with S100A12 and S100A13...
In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitorD S Bundschuh
Department of Pharmacology, Byk Gulden, P O Box 10 03 10, 78403 Konstanz, Germany
J Pharmacol Exp Ther 297:280-90. 2001..These results, coupled with the in vitro effects of roflumilast on inflammatory cells, suggest that roflumilast represents a potential new drug for the treatment of asthma and chronic obstructive pulmonary disease...
Phosphodiesterase 4 inhibitors for the treatment of COPDGraham Sturton
Bayer plc, Pharma Research, Stoke Court, Stoke Poges, Slough SL2 4LY, Berkshire, UK
Chest 121:192S-196S. 2002..The initial clinical data on the most advanced compound, cilomilast, were indeed encouraging. However, full knowledge of the therapeutic value of this novel compound class awaits the outcome of longer term clinical trials...
2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitutionStephen Connolly
Medicinal Chemistry, Discovery Bioscience, Molecular Biology and Physical and Metabolic Sciences Departments, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leics LE11 5RH, U K
J Med Chem 47:3320-3. 2004..Evidently, a flipping of the pyridine ring between these new inhibitors allows the piperidine to interact with different residues and confer excellent selectivity...
The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activitiesTetsuo Toga
Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan Inc, Taketoyo, Aichi, Japan
J Pharmacol Sci 105:207-10. 2007..Therefore, CJ-033466 has the potential to be a drug with higher therapeutic efficacy and less cardiac risk than both cisapride and mosapride...
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in ratsDavid H Overstreet
Department of Psychiatry, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, CB 7178, Chapel Hill, NC 27599 7178, USA
Psychopharmacology (Berl) 167:344-52. 2003..The deficits in social interaction behavior following withdrawal from continuous ethanol exposure can be reduced following acute treatments with 5-HT(2C) antagonists or 5-HT(1A) agonists...
5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in ratsYasuharu Kimura
Pharmacology Research Labs, Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
Eur J Pharmacol 589:157-62. 2008....
Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptorsA A Harrison
Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
J Pharmacol Exp Ther 297:316-25. 2001..In conclusion, the present data support the hypothesis that serotonin exerts an inhibitory influence on reward processes...
Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramineG A Higgins
PRBN-B, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
Br J Pharmacol 133:459-66. 2001..An attenuation of the hyperlocomotor response was also observed following MDL100,907. These findings suggest that 5-HT(2C) receptor activation can inhibit the expression of behaviours mediated through other 5-HT receptor subtypes...
A reporter gene assay for screening of PDE4 subtype selective inhibitorsRoop Singh Bora
Department of Biotechnology, Ranbaxy Research Laboratories, Plot No 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122001, India
Biochem Biophys Res Commun 356:153-8. 2007..This methods provide a novel, simple and sensitive assay for high throughput screening of PDE4 subtype selective inhibitors for treatment of asthma and COPD...
Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotineA J Grottick
PRBN-B, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Psychopharmacology (Berl) 157:292-8. 2001..CONCLUSIONS: The present data support an involvement for the 5-HT(2C) receptor in mediating mesolimbic DA functioning as assessed by changes in behaviours indicative of nicotine reward...
Activation of the serotonergic 5-HT1A receptor in the paraventricular nucleus of the hypothalamus inhibits water intake and increases urinary excretion in water-deprived ratsPatrícia de Souza Villa
Department of Physiology, São Paulo State University at Araraquara, UNESP, Brazil
Regul Pept 150:14-20. 2008..We suggest that antidipsogenic and diuretic responses seem to be mediated via 5-HT(1A) receptors of the lateral-medial posterior magnocellular region of the PVN in water-deprived rats...
Serotonin 1A receptor agonists reverse respiratory abnormalities in spinal cord-injured ratsYang Dong Teng
Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20057, USA
J Neurosci 23:4182-9. 2003..p.; n = 3) given 20 min before 8-OH-DPAT, prevented 8-OH-DPAT from restoring respiration to normal. Our results demonstrate that drugs that stimulate 5-HT1A receptors counteract respiratory abnormalities in conscious rats after SCI...
m-CPP-induced self-grooming is mediated by 5-HT2C receptorsMarton Graf
Laboratory of Neurochemistry and Experimental Medicine, National Institute of Psychiatry and Neurology, Huvosvolgyi ut 116, Budapest H-1021, Hungary
Behav Brain Res 142:175-9. 2003..Our studies provide evidence that direct activation of 5-HT(2C) receptors mediate m-CPP-induced self-grooming and the depletion of brain 5-HT sensitizes these receptors...
5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activationElizabeth A Hackler
Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
J Pharmacol Exp Ther 320:1023-9. 2007..In conclusion, the brain activation signals produced by anxiogenic doses of both m-CPP and FG-7142 are mediated at least partially by the 5-HT(2C) receptor, indicating that this receptor is a key component in anxiogenic neural circuitry...
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognitionZ Huang
Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
Biochem Pharmacol 73:1971-81. 2007..Therefore, L-454,560 is a novel PDE4 inhibitor with an overall in vivo efficacy profile at least comparable to roflumilast and clearly superior to cilomilast...
Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonistK J Damjanoska
Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA
J Pharmacol Exp Ther 304:1209-16. 2003..The data suggest that Ro 60-0175 increases hormone secretion by mechanisms independent of the activation of 5-HT(2C) and/or 5-HT(2A) receptors and suggest that Ro 60-0175 is not a highly selective 5-HT(2C) receptor agonist...
Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J miceRandy L Smith
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Psychopharmacology (Berl) 166:61-8. 2003....
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterizationWilliam J Thomsen
Arena Pharmaceuticals, Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121, USA
J Pharmacol Exp Ther 325:577-87. 2008..Upon discontinuation, body weight returned to control levels. These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity...
PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathwaysHyun Jeong Kwak
Division of Cardiovascular Diseases, Department of Biomedical Sciences, National Institutes of Health, 194 Tongillo, Eunpyung Gu, Seoul 122 701, Republic of Korea
Cell Signal 20:803-14. 2008..Our study suggests a possibility of PDE4 inhibitor roflumilast as a potential therapeutic agent against myocardial ischemia/reperfusion (I/R) injury...
Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypesAkihiko Yonezawa
Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 4 4 1 Komatsushima, Aoba ku, Sendai 981 8558, Japan
Pharmacol Biochem Behav 88:367-73. 2008..0 mg/kg) of m-CPP. Furthermore, the results of the present study also indicate that the corset test employed in this study may be useful for detecting the proejaculatory effect of the compounds...
Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and miceFrank C Barone
Discovery Research, High Throughput Biology, GlaxoSmithKline, King of Prussia, PA 19406, USA
Pharmacology 81:11-7. 2008..In this study, the effects of PDE4 inhibition were assessed in a model of stress-induced defecation previously demonstrated to be due to increased colonic transit/evacuation...
Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axisSusan K Hemrick-Luecke
Neuroscience Research Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0510, Indianapolis, IN 46285, USA
Neuropharmacology 42:162-9. 2002..Our findings implicate 5-HT(2A) receptors rather than 5-HT(2C) receptors in mediating increases in rat serum corticosterone produced by direct-acting 5-HT(2) receptor agonists in vivo...
Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonistC Defraiteur
Cyclotron Research Center, Liege University, Liege, Belgium
Br J Pharmacol 152:952-8. 2007....
Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonismHiroshi Takeda
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita ku, Sapporo, Japan
Gastroenterology 134:2004-13. 2008..Rikkunshito, a kampo preparation, is known to alleviate such adverse reactions. In this study, we attempted to clarify the mechanism...
m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptorsG Di Giovanni
Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro (Chieti, Italy
Neuroscience 103:111-6. 2001..It is concluded that stimulation of serotonin-2C receptors by m-chlorophenylpiperazine activates non-dopaminergic (presumably GABA-containing) neurons in the substantia nigra pars reticulata and ventral tegmental area...
Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylanilineAlan M Jeffrey
New York Medical College, Department of Pathology, Valhalla, NY 10595, USA
Drug Chem Toxicol 25:93-107. 2002..In the absence of a pattern of compound-related spots, we conclude that RF does not form DNA adducts having the potential to initiate neoplasia in these three tissues...
Serotonin 2C receptor agonists and the behavioural satiety sequence in miceKatherine N Hewitt
Laboratory of Experimental Psychology, University of Sussex, Falmer, Brighton, Sussex BN1 9QG, UK
Pharmacol Biochem Behav 71:691-700. 2002..These data suggest that Ro 60-0175- and mCPP-induced hypophagia in mice are mediated via activation of 5-HT(2C) receptors and that stimulation of 5-HT(1B) receptors plays only a minor role in mCPP-induced hypophagia...
Dissociation of systemic and hippocampal modulation of rat locomotor activity by 5-HT(2C) receptorsH Takahashi
Department of Physiology, School of Medicine, Hamamatsu University, 3600 Handa-cho, Hamamatsu-shi, Shizuoka-ken 431-3192, Japan
Neurosci Res 40:97-103. 2001..The present study demonstrates that the 5-HT(2C) receptors in the hippocampus act to increase rat locomotor activity...
Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in ratsMagdalena Zaniewska
Laboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 31 343 Krakow, 12 Smetna, Poland
Eur J Pharmacol 571:156-65. 2007....
Stimulation of 5-hydroxytryptamine (5-HT(2C) ) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortexLaura Pozzi
Mario Negri Institute of Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy
J Neurochem 82:93-100. 2002....
5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus mazeNicholas Jones
Department of Psychology, University College London, Gower Street, London WC1E 6BT, UK
Psychopharmacology (Berl) 164:214-20. 2002..This study aimed to examine the involvement of the 5-HT2C receptor in the unconditioned fear responses observed in the UEEPM (after an acute dose of mCPP) by pre-treatment with the selective 5-HT2C receptor antagonist SB-242084...
LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviourLeann P Quinn
Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
J Neurosci Methods 130:83-92. 2003....
Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparationsRegina Draheim
Department of Pharmacology, elbion AG, Radebeul, Germany
J Pharmacol Exp Ther 308:555-63. 2004..The reduced activity in human blood may be related to high plasma protein binding. Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis...
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challengeC Louw
Internal Medicine, Lung and Allergy Unit, University of Stellenbosch, School of Medicine, Cape Town, South Africa
Respiration 74:411-7. 2007..Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, is currently in clinical development for the treatment of asthma...
Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockadeAgnès L Auclair
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France
Neuropsychopharmacology 31:1900-9. 2006....
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases]Xiao-dong Xia
Zhonghua Jie He He Hu Xi Za Zhi 27:57-9. 2004
Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthmaJ Bousquet
, Montpellier, France
Allergy 61:72-8. 2006..CONCLUSIONS: Once daily, oral roflumilast 500 microg was comparable with inhaled twice-daily BDP (400 microg/day) in improving pulmonary function and asthma symptoms, and reducing rescue medication use in patients with asthma...
Role of 5-HT receptor antagonists in mediating intracavernous pressure response induced by fluvoxamine in conscious ratsNaoki Aizawa
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
J Sex Med 4:1108-16. 2007..It has been reported that selective serotonin reuptake inhibitor (SSRI) may cause sexual dysfunction...
ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbensZhu Li
Psychiatry Department, Psychopharmacology Division, Vanderbilt University School of Medicine, Suite 306, 1601 23rd Ave S, Nashville, TN 37212, USA
Psychopharmacology (Berl) 183:144-53. 2005..However, pretreatment with the 5-HT(2A/2C) receptor antagonist SR46349-B with haloperidol increased both mPFC and NAC DA release, suggesting that both 5-HT(2A) and 5-HT(2C) properties may be important for atypical APD effects...
Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivoSylvia Navailles
, Bordeaux Cedex, France
Biol Psychiatry 59:568-75. 2006..3 and 1 mg/kg). CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo...
WAY 405, a new silent 5-HT (1A) receptor antagonist with low affinity for vascular alpha (1)-adrenoceptorsR Villalobos-Molina
, ,
Auton Autacoid Pharmacol 25:185-9. 2005..4 The results show that in the control of blood pressure the new compound, WAY 405, behaves as a silent 5-HT(1A) receptor antagonist in the anaesthetized rat, also having low affinity for vascular alpha(1)-adrenoceptors...
Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbensPhilippe De Deurwaerdère
Unité Mixte de Recherche Centre National de la Recherche Scientifique 5541 Université Victor Segalen Bordeaux 2, Boîte Postale 31, 33076 Bordeaux Cedex, France
J Neurosci 24:3235-41. 2004....
Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram powerSandor Kantor
Laboratory of Neurochemistry and Experimental Medicine, National Institute of Psychiatry and Neurology, Budapest, Hungary
J Pharmacol Exp Ther 315:921-30. 2005..In contrast, acute CDP administration, based on spectral analysis of the EEG, produced a more superficial sleep along with a decreased activity...
Research Grants
- STRUCTURE-FUNCTION IN LOW-RESISTANCE JUNCTIONSCamillo Peracchia; Fiscal Year: 1993..by testing their potential interaction with amphiphilic connexin domains and the effects of xanthines and aminopyridines. The nature of extracellular connexin-connexin interactions will be studied by expressing connexins ..
- METVAN: A Novel Anticancer AgentOSMOND D CRUZ; Fiscal Year: 2003..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
- FLP-102: Rationally Engineered Antiviral ProteinOSMOND D CRUZ; Fiscal Year: 2003..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
- Stampidine: A Novel Broad-Spectrum Anti-HIV MicrobicideOSMOND D CRUZ; Fiscal Year: 2005..Specific Aims 1 and 2 may provide the foundation for the clinical development of STAMP in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
- Phase II SBIR: WHI-07: A Novel Dual-Function MicrobicideOSMOND D CRUZ; Fiscal Year: 2005....
- Transmitter Repletion: Key to Phrenic-Diaphragm FunctionErik van Lunteren; Fiscal Year: 2005..These studies may lead to novel therapeutic approaches to respiratory muscle impairment and resulting hypercapnic respiratory failure for conditions which produce neuromuscular junction dysfunction. ..
- NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITYOSMOND D CRUZ; Fiscal Year: 2001..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
- PHI 346: A Novel Dual-Function MicrobicideOSMOND D CRUZ; Fiscal Year: 2003..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
- PHI-443: Novel Non-Spermicidal Anti-HIV MicrobicideOSMOND D CRUZ; Fiscal Year: 2003..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
- Vanadocenes as a New Class of Spermicidal DrugsOSMOND D CRUZ; Fiscal Year: 2007....
- Viral-induced Adaptation of Neutrophil Response in ARDSJERRY NICK; Fiscal Year: 2007..End of Abstract) ..
- Effects of Chronic THC in AdolescencePeter J Winsauer; Fiscal Year: 2010..Together, data from these experiments will demonstrate how drug abuse and hormonal status during adolescence may permanently alter brain function and the liability of subsequent abuse of A9-THC. ..
- Neural Mechanism of Drug-Seeking BehaviorJanet L Neisewander; Fiscal Year: 2010..Understanding these circuits will likely have important implications for developing treatments for cocaine dependence. ..
- A Thermo Electron LTQ Mass SpectrometerJoseph Zaia; Fiscal Year: 2006..The costs of instrument operation, supplies, and service contract will be shared by the users, as stated in their support letters. The salary for the instrument operator will be provided by the Dean of BU School of Medicine. ..
- Drugs as conditioned reinforcers and/or enhancers of social reward in adolescentsJanet Neisewander; Fiscal Year: 2007..The findings could potentially initiate a line of investigation on neural mechanisms involved in these interactions, which may in turn provide insight for understanding and treating drug abuse and dependence. ..
- Molecular Epidemiology, Virulence, and Genomic Characterization of UreaplasmasKen Waites; Fiscal Year: 2007....
- CHEMICAL/BEHAVIORAL STUDIES ON HALLUCINOGENIC AGENTSRICHARD GLENNON; Fiscal Year: 2007..This will eventually lead to a better understanding of abuse prevention and treatment modalities. ..
- CB1 Modulation of Opioid Peptides and Ethanol IntakeLoren Parsons; Fiscal Year: 2007..abstract_text> ..
- 5-HTIB RECEPTORS AND MECHANISMS OF ETHANOL REINFORCEMENTLoren Parsons; Fiscal Year: 2005..abstract_text> ..
- CHEMICAL/BEHAVIORAL STUDIES ON HALLUCINOGENIC AGENTSRICHARD GLENNON; Fiscal Year: 1993..New agents are proposed for synthesis that will aid in solving these problems...
- Limbic-cortical involvement in drug seekingJanet Neisewander; Fiscal Year: 2006..The findings may be useful for developing behavioral and pharmacological treatments for cocaine dependence. ..
- BEHAVIORAL & PHARMACOLOGICAL ANALYSIS OF DRUGS OF ABUSEJERROLD WINTER; Fiscal Year: 1991..A long-term objective of the proposed research is to achieve an understanding of these complex behavioral effects in biochemical terms and thus to facilitate rational clinical intervention...
- Neural Mechanism of Drug-Seeking BehaviorJanet L Neisewander; Fiscal Year: 2010..Understanding these circuits will likely have important implications for developing treatments for cocaine dependence. ..
- AMBIENT PARTICULATE MATTERS POISON CARDIAC ION CHANNELSDesuo Wang; Fiscal Year: 2005....
- NEURAL MECHANISMS OF DRUG SEEKING BEHAVIORJanet Neisewander; Fiscal Year: 2000..If confirmed, the findings would suggest a new pharmacologic treatment strategy for cocaine dependence. ..
- CNS VIRAL INJURY AND VULNERABILITY TO OPIATE DRUG ABUSEMarylou Solbrig; Fiscal Year: 2002..At the conclusion of the grant period, the requisite skills in behavioral pharmacology, neuropharmacology and molecular biology for continued work in the study and treatment of drug addiction will have been acquired by the candidate. ..
- EFFECTS OF DIOXINS (TCDD) ON CARDIAC ION CHANNELSDesuo Wang; Fiscal Year: 2003....
- BEHAVIORAL AND PHARMACOLOGIC ANALYSIS OF DRUG OF ABUSEJERROLD WINTER; Fiscal Year: 2000....
- Viral neuropathology neuropeptides and epilepsyMarylou Solbrig; Fiscal Year: 2005....
- NEURAL MECHANISMS OF DRUG SEEKING BEHAVIORJanet Neisewander; Fiscal Year: 2005..These experiments will help to elucidate 5-HT mechanisms involved in incentive motivation for cocaine and will likely have important implications for developing treatments for cocaine dependence. ..
- INFLAMMATION & CORTICOSTEROID RESPONSES IN SEVERE ASTHMAKIAN CHUNG; Fiscal Year: 2005..The molecular mechanisms underlying loss of CR will be examined. These studies should lead to more effective therapies for chronic severe asthma. ..
- BEHAVIORAL & PHARMACOLOGICAL ANALYSIS OF DRUGS OF ABUSEJERROLD WINTER; Fiscal Year: 2005..abstract_text> ..
- Glycosaminoglycan-Protein BindingJoseph Zaia; Fiscal Year: 2006..abstract_text> ..
